Nubain, Nalbuphine

Nubain, Nalbuphine Newswire

Comprehensive Real-Time News Feed for Nubain, Nalbuphine (generic).

Results 1 - 20 of 43 in Nubain, Nalbuphine (generic)

  1. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Monday Nov 17 | Business Wire

    Company units were up 2.6%. )--Clear Channel Spectacolor, bedrijfsonderdeel van Clear Channel Outdoor , dochtermaatschappij van iHeartMedia Inc. , heeft vandaag het grootste, mee... )--Fitch Ratings has assigned an 'A+' rating to Duke Energy Progress, Inc.'s proposed new $700 million dual tranche offering of first mortgage bonds.

    Comment?

  2. Trevi Therapeutics to Present at the Stifel 2014 Healthcare ConferenceRead the original story

    Monday Nov 17 | Business Wire

    Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus . Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions.

    Comment?

  3. Clinical Trial Website Launches in Support of Pivotal Trial in Prurigo NodularisRead the original story

    Friday Nov 14 | Freshnews

    MediciGlobal has launched a new website on behalf of Trevi Therapeutics, Inc. to provide access to information on a clinical trial for prurigo nodularis, considered one of the most severe forms of pruritus . Prurigo nodularis, also known as nodular prurigo, is characterized by painful nodules that itch so intensely that the perpetual cycle of itch, scratch, bleed, and scarring lasts for years or even decades.

    Comment?

  4. Clinical Trial Website Launches in Support of Pivotal Trial in Prurigo NodularisRead the original story w/Photo

    Thursday Nov 13 | Sys-Con Media

    Prurigo nodularis, also known as nodular prurigo, is characterized by painful nodules that itch so intensely that the perpetual cycle of itch, scratch, bleed, and scarring lasts for years or even decades. As a result, prurigo nodularis can negatively affect a person's quality of life-interfering with daily activities, social interactions, and sleep.

    Comment?

  5. Trevi Therapeutics Selected to Exhibit Poster at American Society of Nephrology Kidney Week 2014Read the original story

    Tuesday Nov 11 | Customer Interaction Solutions

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, was selected to exhibit a poster at the American Society of Nephrology's Kidney Week 2014 , which takes place November 13th-16th at the Pennsylvania Convention Center in Philadelphia, PA. Poster #TH-PO730, titled " Exploring Clinical and Pharmacological Effects of Nalbuphine HCl Oral Tablets in Hemodialysis Subjects wth Pruritus, " reports that Nalbuphine administered as oral nalbuphine HCl ER tablets was safe and well tolerated up to 240 mgs and that there appeared to be a dose-dependent reduction in VAS scores related to itch.

    Comment?

  6. TPG Biotech backs Trevi TherapeuticsRead the original story w/Photo

    Friday Nov 7 | PE Hub

    Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors. The Company is continuing enrollment in the U.S. for its uremic pruritus trial, a pivotal study expected to enroll approximately 360 patients, and expects to initiate enrollment at European sites for this study by year-end.

    Comment?

  7. Trevi Therapeutics Announces Second Closing of $26 Million Series B...Read the original story

    Wednesday Nov 5 | Venture Capital Access Online

    Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors. The Company is continuing enrollment in the U.S. for its uremic pruritus trial, a pivotal study expected to enroll approximately 360 patients, and expects to initiate enrollment at European sites for this study by year-end.

    Comment?

  8. Trevi Therapeutics Reels In $26 MillionRead the original story

    Thursday Nov 6 | BioSpace

    Trevi Therapeutics Announces Second Closing of $26 Million Series B Financing for Development of Nalbuphine ER Uremic pruritus trial enrolling ahead of schedule and Company preparing to initiate trial in prurigo nodularis NEW HAVEN, Conn.-- --Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors.

    Comment?

  9. Trevi Therapeutics Announces Second Closing of $26 Million Series B...Read the original story w/Photo

    Thursday Nov 6 | Business Wire

    Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech , the life science venture investment arm of TPG, and existing angel investors. The Company is continuing enrollment in the U.S. for its uremic pruritus trial, a pivotal study expected to enroll approximately 360 patients, and expects to initiate enrollment at European sites for this study by year-end.

    Comment?

  10. Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global,...Read the original story

    Wednesday Oct 29 | PRWeb

    DeepResearchReports.com adds "2014 Deep Research Report on Global and China Naltrexone HCL Industry" and "2014 Deep Research Report on Global and China Nalbuphine HCL Industry" to its research database. 2014 Deep Research Report on Global and China Naltrexone HCL Industry" is a professional and in-depth research report on the China Naltrexone HCLmarket.

    Comment?

  11. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Wednesday Oct 29 | Business Wire

    The notes will constitute direct, unconditional and uns... )--FUND A db x-trackers StoxxA Europe 600 Oil & Gas Short Daily UCITS ETF DEALING DATE A 28-Oct-14 NAV PER SHARE A EUR17.9062 NUMBER OF SHARES IN ISSUE A 210,623 CODE A )--SOFC component/system developer and manufacturer WATT Fuel Cell Corp., announces the official grand opening of its new facility in Mt. Pleasant, Penn.

    Comment?

  12. Research and Markets: Global and Chinese Nalbuphine HCL Industry Report 2014Read the original story

    Wednesday Oct 29 | Business Wire

    Global and Chinese Nalbuphine HCL Industry Report 2014 is a professional and in-depth study on the current state of the global Nalbuphine HCLindustry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.

    Comment?

  13. Gil Yosipovitch, M.D. Joins Trevi Therapeutics??? Clinical Advisory BoardRead the original story

    Oct 1, 2014 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage development biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that Gil Yosipovitch, M.D. has joined its Clinical Advisory Board. In that role, Dr. Yosipovitch, Professor and Chair of The Department of Dermatology and Director of the Temple Itch Center at the Temple University School of Medicine in Philadelphia, Pennsylvania, will work closely with Trevi's Co-founders, Jennifer Good and Thomas Sciascia, M.D., on the Company's development programs.

    Comment?

  14. Gil Yosipovitch, M.D. Joins Trevi Therapeutics' Clinical Advisory BoardRead the original story

    Oct 1, 2014 | Freshnews

    Trevi Therapeutics, Inc. , a late-stage development biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that Gil Yosipovitch, M.D. has joined its Clinical Advisory Board. In that role, Dr. Yosipovitch, Professor and Chair of The Department of Dermatology and Director of the Temple Itch Center at the Temple University School of Medicine in Philadelphia, Pennsylvania, will work closely with Trevi's Co-founders, Jennifer Good and Thomas Sciascia, M.D., on the Company's development programs.

    Comment?

  15. Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting...Read the original story

    Sep 17, 2014 | Hispanic Business

    This rigorous study characterized the pharmacokinetics of Nalbuphine ER in renally impaired patients, established that the drug was well tolerated across the entire dose range, and demonstrated the drug is not affected by the dialysis process. We also observed compelling proof-of-concept data in the reduction of itching over the two-week period in the hemodialysis patients.

    Comment?

  16. Trevi Therapeutics Selected To Exhibit Poster At 2014 Annual Meeting Of TheRead the original story

    Sep 9, 2014 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, was selected to exhibit a poster at the 2014 Annual Meeting of the American College of Clinical Pharmacology, which takes place September 14th - 16th at the Westin Peachtree Plaza and AmericasMart in Atlanta, GA.

    Comment?

  17. Trevi Therapeutics Selected To Exhibit Poster At 2014 Annual Meeting of theRead the original story

    Sep 9, 2014 | BioSpace

    Title of Abstract: Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses New Haven, CT, September 9, 2014 - Trevi Therapeutics, Inc. , a late-stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, was selected to exhibit a poster at the 2014 Annual Meeting of the American College of Clinical Pharmacology, which takes place September 14th - 16th at the Westin Peachtree Plaza and AmericasMart in Atlanta, GA.

    Comment?

  18. Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting...Read the original story

    Sep 9, 2014 | Hispanic Business

    The poster's first author, , MD, Trevi's co-founder and Chief Medical Officer, said, 'Opioids have not historically been well characterized in renally impaired patients. This rigorous study characterized the pharmacokinetics of Nalbuphine ER in renally impaired patients, established that the drug was well tolerated across the entire dose range, and demonstrated the drug is not affected by the dialysis process.

    Comment?

  19. Ex-BSP asset caught making billsRead the original story w/Photo

    Sep 7, 2014 | Sun-Star

    POLICE arrested one man suspected of making fake money and confiscated some P10,000 worth of bills from him in Barangay Day-as, Cebu City yesterday dawn. City Intelligence Branch Chief Romeo Santander said that his team caught Nicolas Herrera, 54; Philip Erasmo, 41; and Maria Cielo Caballes, 30, after they saw the three allegedly cutting fake bills at 1 a.m. It was the third time this year the police arrested Herrera, whose former job was helping the central bank monitor the manufacturer of fake currency.

    Comment?

  20. Narcan antidote to be offered by CVSRead the original story w/Photo

    Aug 27, 2014 | Examiner.com

    CVS Caremark will soon offer Narcan , an antidote for opioid overdoses such as heroin, Oxycotin, morphine as well as others drugs in this class of narcotic analgesics.

    Comment?